NASDAQ: GANXGain Therapeutics Inc Stock
$3.39+0.22 (+6.94%)
Updated Apr 23, 2024
GANX Price
$3.39
Fair Value Price
$0.70
Market Cap
$54.98M
52 Week Low
$2.00
52 Week High
$5.65
P/E
-1.98x
P/B
4.37x
P/S
769.88x
PEG
N/A
Dividend Yield
N/A
Revenue
$55.18k
Earnings
-$22.27M
Gross Margin
100%
Operating Margin
-40,210.67%
Profit Margin
-40,354.3%
Debt to Equity
0.48
Operating Cash Flow
-$19M
Beta
1.02
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
GANX Overview
Gain Therapeutics, Inc., a biotechnology company, develops treatments for rare genetic diseases and neurological disorders caused by protein misfolding. Using its Site-Directed Enzyme Enhancement Therapy platform, the company discovers allosteric sites on misfolded proteins and identifies proprietary small molecules that bind to these sites, restore protein folding, and treating diseases such as Morquio B disease, GM1 gangliosidosis, neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe disease, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, MD.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GANX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GANX ($3.39) is overvalued by 381.28% relative to our estimate of its Fair Value price of $0.70 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GANX ($3.39) is not significantly undervalued (381.28%) relative to our estimate of its Fair Value price of $0.70 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GANX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GANX due diligence checks available for Premium users.
Be the first to know about important GANX news, forecast changes, insider trades & much more!
GANX News
Valuation
GANX fair value
Fair Value of GANX stock based on Discounted Cash Flow (DCF)
Price
$3.39
Fair Value
$0.70
Overvalued by
381.28%
GANX ($3.39) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GANX ($3.39) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GANX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GANX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.98x
Industry
16.46x
Market
41.92x
GANX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.37x
Industry
5.93x
GANX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GANX's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.7M
Profit Margin
0%
GANX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GANX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$18.6M
Liabilities
$6.0M
Debt to equity
0.48
GANX's short-term assets ($17.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GANX's short-term assets ($17.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GANX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.7M
Investing
$3.1M
Financing
$9.6M
GANX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GANX vs Biotech Stocks
Gain Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.